Mrinal Supriya1, Ng Suat-Chin2, Andrew Sizeland2. 1. Peter MacCallum Cancer Centre, Melbourne, Australia. Electronic address: doctorms77@gmail.com. 2. Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Abstract
PURPOSE: To evaluate the impact of whole-body positron emission tomography in comparison to staging by conventional methods alone in management of patients with head and neck cutaneous squamous cell cancer (cSCC) with confirmed regional nodal metastasis. MATERIALS AND METHODS: This is a retrospective case cohort study carried out at a tertiary referral cancer centre. The participants were thirty-one adults with head and neck cSCC and regional nodal metastasis. The original treatment plan based on conventional cross-sectional imaging and clinical examination was compared to the final treatment plan after additional PET staging to evaluate the impact of 18F-FDG PET-CT on patient management. RESULTS: Addition of 18F-FDG PET-CT did not change the management in 24/31 (77%) of patients. In four cases the 18F-FDG PET-CT failed to pick up biopsy proven metastatic disease. Two patients who had reduced extent of surgery have shown no features of regional failure after one year of follow-up. CONCLUSION: Overall the management in majority of head and neck cSCC patients with regional metastasis does not change by addition of 18F-FDG PET-CT over conventional imaging. Crown
PURPOSE: To evaluate the impact of whole-body positron emission tomography in comparison to staging by conventional methods alone in management of patients with head and neck cutaneous squamous cell cancer (cSCC) with confirmed regional nodal metastasis. MATERIALS AND METHODS: This is a retrospective case cohort study carried out at a tertiary referral cancer centre. The participants were thirty-one adults with head and neck cSCC and regional nodal metastasis. The original treatment plan based on conventional cross-sectional imaging and clinical examination was compared to the final treatment plan after additional PET staging to evaluate the impact of 18F-FDG PET-CT on patient management. RESULTS: Addition of 18F-FDG PET-CT did not change the management in 24/31 (77%) of patients. In four cases the 18F-FDG PET-CT failed to pick up biopsy proven metastatic disease. Two patients who had reduced extent of surgery have shown no features of regional failure after one year of follow-up. CONCLUSION: Overall the management in majority of head and neck cSCC patients with regional metastasis does not change by addition of 18F-FDG PET-CT over conventional imaging. Crown
Authors: Matthew Fox; Marc Brown; Nicholas Golda; Dori Goldberg; Christopher Miller; Melissa Pugliano-Mauro; Chrysalyne Schmults; Thuzar Shin; Thomas Stasko; Yaohui G Xu; Kishwer Nehal Journal: J Am Acad Dermatol Date: 2018-09-15 Impact factor: 11.527
Authors: Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams Journal: Cochrane Database Syst Rev Date: 2019-07-01
Authors: Gabriel C Fine; Matthew F Covington; Bhasker R Koppula; Ahmed Ebada Salem; Richard H Wiggins; John M Hoffman; Kathryn A Morton Journal: Cancers (Basel) Date: 2022-06-08 Impact factor: 6.575